← Back to Search

Norepinephrine Reuptake Inhibitor

Drugs + Hand Training for Spinal Cord Injury

Phase 1
Recruiting
Led By Lynda M Murray, PhD
Research Sponsored by Bronx VA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured every 5-10 minutes, for up to 4 hours. change will be compared to baseline.

Summary

This trial is studying if drugs & hand training exercises can help strengthen brain-spinal cord connections after injury, with assessments of nerve transmission, muscle response, and motor performance.

Who is the study for?
This trial is for adults aged 18-65 with stable chronic spinal cord injury at or above C8, who have some hand muscle activity and are on a consistent medication and rehab plan. Participants must avoid alcohol, smoking, caffeine before visits, not use recreational drugs during the study, and commit to all sessions.
What is being tested?
The study tests if FDA-approved drugs (cyproheptadine, carbidopa-levodopa, atomoxetine) combined with hand exercises can improve brain-spinal cord connections in people with chronic spinal cord injuries. It measures nerve transmission and muscle response through noninvasive stimulation.
What are the potential side effects?
Potential side effects of the drugs may include drowsiness from cyproheptadine; nausea or low blood pressure from carbidopa-levodopa; increased heart rate or dry mouth from atomoxetine. Side effects vary by individual.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured every 5-10 minutes, for up to 4 hours. change will be compared to baseline.
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured every 5-10 minutes, for up to 4 hours. change will be compared to baseline. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assessing task performance (dexterity)
Secondary study objectives
Assessing cortical plasticity
Assessing corticospinal plasticity
Assessing spinal plasticity
+8 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: CPH + hand trainingExperimental Treatment1 Intervention
A single dose of Cyproheptadine (CPH) (8 mg) will be administered. Supplied as 2 over-encapsulated pills of 4 mg each.
Group II: CD-LD + hand trainingExperimental Treatment1 Intervention
A single dose of IR Carbidopa-levodopa (CD-LD) (50/200 mg) will be administered. Supplied as 2 over-encapsulated pills (25 mg carbidopa / 100 mg levodopa each).
Group III: ATX + hand trainingExperimental Treatment1 Intervention
A single dose of Atomoxetine (ATX) (40 mg) will be administered. Supplied as 1 over-encapsulated pill of 40 mg plus 1 placebo capsule.
Group IV: Placebo + hand trainingPlacebo Group1 Intervention
A single dose of Placebo will be administered. Supplied as 2 gelatin capsules, identical in number, size, shape and color, filled with microcrystalline cellulose.

Find a Location

Who is running the clinical trial?

Bronx VA Medical CenterLead Sponsor
21 Previous Clinical Trials
1,318 Total Patients Enrolled
Lynda M Murray, PhDPrincipal InvestigatorBronx VA Medical Center / James J. Peters Veterans Affairs Medical Center

Media Library

Atomoxetine (Norepinephrine Reuptake Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05708274 — Phase 1
Spinal Cord Injury Research Study Groups: CD-LD + hand training, Placebo + hand training, CPH + hand training, ATX + hand training
Spinal Cord Injury Clinical Trial 2023: Atomoxetine Highlights & Side Effects. Trial Name: NCT05708274 — Phase 1
Atomoxetine (Norepinephrine Reuptake Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05708274 — Phase 1
~6 spots leftby Jul 2025